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Sutherlandia frutescens R.BR. (Fabaceae) which belongs to the class Magnoliopsida and the 
order Fabales, is one of South Africa’s medicinal plants traditionally used for the treatment of 
several ailments. It is used as an internal medication for treating stomach problems, fever and 
backache and can be used topically in treating wounds and eyes infections (19). The plants 
extracts have been shown to exhibit an anti-proliferative effect on cancer cells (6). 
S. frutescens is considered as a safe medicinal plant for the treatment several ailments such as 
tuberculosis, fatigue, peptic ulcers, gastritis and anxiety.  
 
The Fabaceae family contains 600 genera and 1200 species, distributed throughout the world. 
The genus Sutherlandia was named after James Sutherland and the species, frutescens, means 
bushy in Latin. Other related species of Sutherlandia includes; S. microphylla, S. montana 
(mountain cancer bush) and S. tomentosa. The Sutherlandia species cannot be easily 
differentiated as they closely resemble each other. These species are unevenly distributed in 
the Western Cape Province in South Africa and are also found in Botswana and Namibia 
(Figure 1). This family of plants is represented by 134 genera and more than 1300 species. 
S. frutescens comprises of six taxa and is common in South Africa (20). The significant 
characteristics distinguishing the different taxa are habitat, orientation of fruit stipe, shape and 
pubescence of the leaflets and the shape of the pods. 
 
 
 
 
 
 
Figure 1. The shaded area, marks the geographical distribution of S. frutescens in the Western, Eastern 
and Northern Cape provinces of South Africa. 
 
The medicinal application of S. frutescens originated from the Khoi and Nama people. They 
used decoctions to treat fevers, wash wounds and for a variety of other ailments. There are 
different dialects in South Africa and each one describes the plant differently. The traditional 
Tswana name given to S. frutescens is Phetola, which is in accordance to the favorable 
outcome when used in treating an illness. The Northern Sotho name for S. frutescens is 
Lerumo-lamadi, (spear for the blood) and refers to its use as a blood-purifier or an all-purpose 
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tonic. The Zulu name, Insiswa, means that it dispels darkness and is used as an anti-
depressant and as a calming tea. It is called Kankerbos in Afrikaans and used in the treatment 
of cancer and as an anti-diabetic treatment (21). 
 
Sutherlandia frutescens has soft, saw-like edged leaves which are hairy on the surface and 
have a silvery appearance (22). The plant produces red flowers from July to December. Its 
fruit is an inflated leathery pod that is 1.3 – 2 mm long. It is a robust, fast growing plant 
which tolerates all soil types. Although S. frutescens occurs in summer and winter rainfall 
regions, it thrives in full sun and is drought resistant. Cultivation of S. frutescens is usually 
done on a large scale in autumn or spring and germination occurs 2-3 weeks later.  
 
 
 
 
 
 
 
 
Figure 2 Flowering S. frutescens found on Table Mountain, Western Cape, South Africa. 
 
Commercially available S. frutescens is produced from organically cultivated plant material 
(23). During harvesting, only leaves and sometimes tender stems are selected. After the 
harvesting of S. frutescens, the selected leaves and tender stems are dried at a temperature of 
40 OC or directly under sunlight for a few days. The flowers, pods and seeds are discarded. 
The dry product is stored under controlled conditions (dry, hygienic and ventilated) before its 
processing. During processing, the dried leaves and tender stems are ground into powder 
using a suitable mill. The powder is subsequently sieved, removing any hard pieces of dried 
stems.  
 
Sutherlandia frutescens is commercially available as capsules that contain the raw plant 
material in powdered form. These capsules are gamma irradiated to achieve microbiological 
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Many bioactive compounds have been discovered and many drugs prescribed today are 
derived from secondary plant metabolites. These compounds vary widely in chemical 
structure and function and are classified accordingly. A list of these secondary plant products 
includes compounds such as terpenoids, flavonoids, phenolics, polyisoprenes, cynogenic 
glycosides, carotenoids and alkaloids. Although these secondary plant products are common, 
they are, however, plant species specific. 
 
Most of the phenolic compounds in plants belong to the flavonoid group. The flavonoids are 
mostly found in fruits, vegetables and extracts obtained from plants. As such, they are natural 
dietary disease-preventing, health-promoting, anti-ageing substances (2). Flavonoids and 
some of the aromatic amino-acids such as phenylalanine, tryptophan and tyrosine are 
synthesised via the shikimic pathway in the plastids of plants which may be categorized in 
three different steps. The first step is the condensation of phosphoenolpyruvate (PEP) and 
erythrose-4-phosphate, which leads to the formation of shikimic acid. The shikimic acid is 
converted to chorismate, in a number of enzyme catalyzed reactions. Chorismate is 
subsequently converted to several products which includes the flavonoids (38, 39 and 40). 
The different types of flavonoids (Figure 3) are classified based on the general structure 
derived from the C15 flavan ring system. Some of the classes include flavonols, flavanones, 
flavones, flavanols, isoflavone and anthocyanidins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flavonoids identified in medicinal plants. 
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produced by the liver and functions in increasing the amount of circulatory mineralocorticoids 
(127) while ACTH has little effect in the rate of aldosterone secretion. 
 
A decrease in blood Na+ and blood pressure is detected by the mascula densa and 
juxtaglomerular cells of the nephron (Figure 9). The resulting effect is the secretion of 
enzyme renin which converts plasma protein angiotensinogen to angiotensin I. Circulatory 
angiotensin I in the lungs is cleaved by angiotensin converting enzyme (ACE) to form 
angiotensin II. This subsequently acts on the glomerulosa cells to activate the synthesis of 
aldosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of the regulation of aldosterone secretion. 
 
The activation of aldosterone synthesis can also be controlled by factors such as extracellular 
potassium (128) due to the effect of potassium on the membrane potential of the adrenal 
glomerulosa cells. The underlying mechanism involves the influx of extracellular Ca+ through 
voltage-gated channels (129). Aldosterone synthesis can however be slightly reduced if there 
is a high Na+ concentration in the extracellular fluid.  
 
The adrenal glands are involved in the different types of stress condition. The stress response 
is sub served by the stress system, which has both central nervous system and peripheral 
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components. Coordination of the stress response is through changes in the activities of the 
brain and hormonal system known as the hypothalamic-pituitary-adrenal (HPA) axis (9). The 
central effectors of the stress response are the corticotrophin releasing hormone (CRH) and 
locus coeruleus-norepineprine (LC-NE)/sympathetic systems. CRH is the major hypothalamic 
regulator of the pituitary-adrenal axis, which stimulates the secretion of ACTH from the 
anterior pituitary. ACTH is a 39 amino acid peptide hormone synthesized as part of a larger 
precursor polypeptide known as proopiomelanocortin (POMC). 
 
During increased periods of physiological or psychological stress and diurnal variation, the 
hypothalamus secretes CRH, which in turn releases ACTH as shown in Figure 10. ACTH 
travels through the blood stream and is almost entirely responsible for the control of 
glucocorticoid production in the adrenals fasciculata and reticularis. These products will 
subsequently move to target cells and initiate gene transcription through transcription factors 
and steroid receptors (SR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of glucocorticoid synthesis by adrenal cortex in stress response. Note 
ACTH and CRH secretion is inhibited by glucocorticoid feedback (130). 
 
Once the glucocorticoid product such as cortisol is at an adequate or excessive amount, it 
exhibits a negative feedback, inhibiting the synthesis and release of CRH, ACTH and arginine 
vasopressin (AVP) from the hypothalamus and ACTH from the anterior pituitary. 
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3.5.2 Physical properties of cytochrome P450 enzymes  
 
The cytochrome P450 enzymes are made up of between 400-500 amino acids. These enzymes 
contain a single heme prosthetic group whose distal axial ligand is formed by a cystein 
residue (179). The protoporphyrin binds to a central iron atom which is a penta- or 
hexacoordinate. The presence of this complex contributes to the cytochrome P450 ability to 
cleave molecular oxygen (180). The mechanism at which substrates bind to cytochrome P450 
enzymes and the subsequent formation and release of product, play an important role in the 
various functions of these enzymes. The bacterial cytochrome P450cam, which catalyses the 
hydroxylation of camphor, has been used as a prototype to understand the structure and 
function of the cytochrome P450 enzymes (181, 182). 
 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Active site of substrate free P450cam. Oxygen atoms are shown in red, nitrogen in blue, sulphur 
in grey and iron in purple. Carbon atoms are shown in black while hydrogen is not shown (182).  
 
3.5.3 Mechanism of P450 enzymes Catalyzed Reactions 
 
The P450 enzymes catalyze reactions designed to promote the removal of lipophilic 
substances, including normal body constituents such as steroids and prostaglandins, together 
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spectrum is identified by an increase in the absorption maximum between 425 nm and 435 nm 
and an absorption minimum between 390 nm and 405 nm (192). Unlike the type I difference 
spectra, type II difference spectra exhibits a shift to longer wavelengths indicating a change 
from a high spin state to a low spin state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Type II difference spectra obtained by the addition of an inhibitor to cytochrome P450 (190). 
 
Reverse type I (modified type II) difference spectra 
 
Reverse type I difference spectra are obtained when high-spin state cytochrome P450 are 
bound to compounds which exhibit hydrophobic characteristics. The exact interaction of these 
ligands is not directly at the heme, but the ligand binds to a different site in the active pocket. 
The reverse type I spectrum can also be obtained when substrates dissociates from enzyme 
complex (193). It is also known as the modified type II and is characterized with an 
absorbance maximum between 409 nm and 445 nm and an absorbance minimum between 365 
nm and 410 nm. The reverse type I closely resembles the type II binding spectrum.  
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4.2.8 Preparation of Adrenodoxin and Adrenodoxin reductase (ADX/ADXR)  
 
Since the adrenodoxin reductase (ADXR) and adrenodoxin (ADX) concentration in the 
mitochondrial preparation which was to be used to study the influence of S. frutescens on 
substrate conversion was inadequate, the protein had to be added to the reaction mixture when 
investigating the catalytic activity of the CYP11B1. The preparation of ADX/ADXR was 
carried out at 4°C using adrenal tissue as previously described by Omura et al. (15). Fresh 
sheep adrenals, 120 g, were de-capsulated and homogenized in 480 ml 0.25 M sucrose 
solution (pH 7.4) containing 10 mM EDTA. The homogenate was centrifuged at 1000 x g for 
15 min. The supernatant was subjected to further centrifugation for 15 min at 9000 x g. The 
pellet obtained, was washed by re-suspension in 450 ml 0.25 M sucrose solution (pH 7.4) and 
centrifuged at 9000 x g for 15 min. The mitochondrial pellet was re-suspended in the smallest 
possible volume of 0.1M Tris-HCl buffer (pH 7.4) and sonicated. The sonicated fraction was 
centrifuged at 150 000 x g for 100 min, to yield a supernatant which contained ADXR and 
ADX. The activity of the ADXR/ADX-preparation was assayed as described below and as it 
was too dilute to use in the substrate conversion assays, the ADXR/ADX preparation was 
subsequently concentrated as described by Swart et al. (233). The assembled concentrator, 
shown in Figure 26, consists of four main components: an upper membrane support fitting, a 
lower membrane support fitting, the sample collecting chamber and a central spacing rod. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Assembled perspex apparatus constructed for concentrating large volumes of dilute protein 
solution. (1) top membrane support fitting, (2) sample inlet, (3) O-ring, (4) central spacing rod, (5) O-ring, 
(6) clamps, (7) bottom membrane support fitting and (8) sample collecting chamber 
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Dialysis tubing, Spectrapor No.1 (20.4 mm 6000-8000 Mr cut-off) used in the concentrator, 
was boiled in distilled water for 5 minutes and rinsed prior to use. Once the apparatus was 
assembled the dialysis tube was stretched and placed over the central spacing rod and the 
upper and lower membrane support fittings screwed onto either end of the rod. The ends of 
the dialysis tube were pulled over the upper and lower membrane support fittings so that 10 
mm of the membrane covered both fittings. The O-rings were then placed over the tube 
covering the membrane support fittings and the dialysis tube sealed onto the supports by two 
circular clamps tightened by stainless steel screws. The sample collecting chamber was filled 
with 0.1M Tris-HCl buffer (pH 7.4) and gently connected to the lower membrane support 
fitting. The ADXR/ADX solution was subsequently loaded into the sealed dialysis tube 
through the solution inlet. With the vent was open the dialysis tube was filled to the lower 
edge of the upper membrane support fitting after which the vent was closed. The solution inlet 
was connected to the reservoir containing the dilute ADXR/ADX solution. The perspex 
apparatus was placed into a 1L beaker containing a 40% PEG solution (m/v in 0.1 M Tris-
HCl buffer (pH 7.4) and stirred at 4°C as shown in Figure 27. 
 
 
Figure 27. Experimental set-up for the concentration of ADX/ADXR solution. 
 
Water which accumulated from the ADX/ADXR solution as a consequence of the osmotic 
pressure differential between the PEG solution and the dilute ADX/ADXR solution was 
removed. The concentration process continued until the ADX/ADXR solution in the sample 
solution reservoir was below the upper edge of the lower membrane support fittings. After 
completion of the concentrating process, the sample collecting chamber was detached from 
the lower membrane support fitting, the concentrated ADXR/ADX solution was collected and 
stored in 1 ml aliquots at -20°C.  
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between 426 nm and 434 nm was obtained (Figure 30 B). The absorbance minimum could not 
be ascertained due to the pigmentation of the extract. However, this spectrum is comparable 
to type II difference spectra. The induced difference spectrum is possibly due to compounds 
in the methanol extract binding directly to the ferric ion and displacing the water molecule. 
The spectrum induced by the chloroform extract (Figure 30 C) exhibits an absorption 
minimum at 420 nm which is indicative of a type I spectrum. The absorbance maximum 
normally observed between 390 nm and 380 nm cannot be easily ascertained, possibly due to 
pigments in the chloroform extract interfering with the absorbance at this wavelength. 
 
Inhibition of steroid-induced difference spectra 
 
Once the interaction of the different S. frutescens extracts with the P450 enzymes had been 
established, the inhibitory effect of the S. frutescens extracts on the binding of natural 
substrates to the enzyme was determined. The binding of PROG (32 µM) to microsomal P450 
enzymes induced a typical type I difference spectra with an absorbance maximum at 387 nm 
and minimum at 419 nm as shown in Figure 31 A. 
 
 
 
 
 
 
        
  
 
 
 
 
 
 
 
 
Figure 31. A: Inhibition of PROG-induced type I difference spectra in adrenal microsomes [cytochrome 
P450] = 0.7 µM, [PROG] = 32 µM ( ), aqueous extract, 1.06 mg ( ), methanol extract, 1.06 mg 
( ) and chloroform extract, 1.06 mg ( ). B: Percentage inhibition of PROG binding to 
microsomal P450 enzyme by S. frutescens extracts. Results are the averages of three independent 
experiments. 
 
Inhibition of PROG binding by the different S. frutescens extracts is shown by the reduction 
in the amplitude of the peaks. The chloroform extract showed an inhibition of 52% which was 
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significantly (P < 0.001) higher than the inhibition by the methanol (22%) and aqueous 
extracts (18%) (Figure 31 B). The inhibition of PREG binding to the microsomal P450 
enzymes was also carried out (data not shown), however the different S. frutescens extracts 
could not affect PREG binding to the enzyme. 
 
The ovine adrenal mitochondrial cytochrome P450 substrate-induced difference spectra are 
shown in Figure 32. 
 
 
 
 
 
 
 
 
 
   
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Inhibition of steroid-induced type I difference spectra by S. frutescens extracts in adrenal 
mitochondrial preparation. A: Inhibition of DOC-induced difference spectra and B: Percentage inhibition 
of DOC binding to CYP11B1, [DOC], 32 µM ( ); C: Inhibition of deoxycortisol-induced difference 
spectra  and D: Percentage inhibition of deoxycortisol binding to CYP11B1 [deoxycortisol], 32 µM 
( ). [Cytochrome P450] = 0.7 µM, aqueous extract, 1.06 mg ( ), methanol extract, 1.06 mg 
( ) and chloroform extract, 1.06 mg ( ). Results are representative of three independent 
experiments. 
 
Both DOC and deoxycortisol induced a type 1 difference spectrum when the substrates bound 
to CYP11B1 in the absence of S. frutescens extracts (Figure 32A and C). Inhibition of steroid 
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Figure 33. Inhibition of substrate-induced type I difference spectra in ovine adrenal mitochondria 
[Cytochrome P450] =0.7 µM, A: [DOC] = ( ) 32 µM. B: [deoxycortisol] = ( ) 32 µM. C: 
[PROG] = ( ) 32 µM. S. frutescens tablets extract, 1.06 mg ( ). D: Percentage inhibition of DOC, 
deoxycortisol and PROG binding to mitochondrial and microsomal P450 enzymes. Results are 
representative of three independent experiments. 
 
Varying degrees of inhibition on substrate binding was observed in the presence of the 
S. frutescens tablet extract. Hence it could be deduced that manufacturing processes may have 
negligible influence on the bioactivity of the S. frutescens tablet extract. The extract inhibited 
the binding of DOC by 21.97%, deoxycortisol by 19.81% and PROG by 12.97%. Statistical 
analysis however shows that the inhibitory effect of this extract on the binding of these 
steroids is not significantly different (P > 0.05).  
 
Saturation binding assay 
 
Since the S. frutescens extracts were shown to inhibit the binding of endogenous steroid 
substrates to the cytochrome P450 enzymes, the inhibitory effects were further investigated in 
order to establish the type of enzyme inhibition. The inhibition of PROG binding to the 
microsomal enzymes was therefore assayed in the presence of various substrate and extract 
concentrations.  
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Figure 34. Hyperbolic saturation binding curves of the inhibitory effect of S. frutescens extracts on PROG 
binding to microsomal P450 enzymes: A: aqueous extracts; D: methanol extracts; and G chloroform 
extract. Double reciprocal plots of the inhibitory effect of S. frutescens extracts on PROG binding: B: 
aqueous extracts E: methanol extracts; H: chloroform extracts. Secondary plot of the slope of 1/ [∆Abs] 
against inhibitor concentration: C: aqueous extracts; F: methanol extracts; I: chloroform extracts. 
[Cytochrome P450]= 0.7 µM; [PROG], (2 µM – 64 µM); aqueous extracts, 0.106 mg - 0.53 mg; methanol 
extracts, 0.074 mg - 0.37 mg; and chloroform extracts 0.074 mg - 0.37 mg. Results are representative of 
two independent experiments. 
 
In the presence of increasing concentrations of S. frutescens extracts, a concentration 
dependent inhibition of PROG binding to the cytochrome P450 enzyme was observed. This 
inhibition was characterized by a concentration-dependent increase in the substrate 
dissociation and a corresponding decrease in the apparent affinity of the cytochrome P450 
enzymes for the substrate. The results obtained with the binding assays which were conducted 
is only a reflection of binding inhibition and is not an indication of whether the catalytic 
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